Skip to main navigation
Skip to search
Skip to main content
University College Cork Home
Home
Profiles
Research units
Research output
Activities
Prizes
Datasets
Impacts
Courses
Press/Media
Search by expertise, name or affiliation
Natalizumab for active Crohn's disease
Subrata Ghosh
, Eran Goldin
, Fiona H. Gordon
, Helmut A. Malchow
, Jørgen Rask-Madsen
, Paul Rutgeerts
, Petr Vyhnálek
, Zdena Zádorová
, Tanya Palmer
, Stephen Donoghue
NHS Lothian
Imperial College Healthcare NHS Trust
Hadassah University Medical Centre
Royal Free London NHS Foundation Trust
Klinikum Leverkusen
University of Copenhagen
KU Leuven
Pardubice Regional Hospital
Kralovske Vinohrady
Elan Pharmaceuticals
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Natalizumab for active Crohn's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Natalizumab
100%
Placebo
45%
Remission
36%
Disease Activity
27%
C Reactive Protein
27%
Integrin
18%
Diseases
9%
Inflammation
9%
Adverse Event
9%
Monoclonal Antibody
9%
Cell Adhesion Proteins
9%
Immunology and Microbiology
Crohn's Disease
100%
Natalizumab
100%
C-Reactive Protein
27%
Integrin
18%
Body Weight
9%
Leukocyte
9%
Monoclonal Antibody
9%
Cell Adhesion Proteins
9%
Parenchyma
9%
Neuroscience
Natalizumab
100%
Placebo
45%
C-Reactive Protein
27%
Quality of Life
27%
Integrin
18%
Parenchyma
9%
Leukocyte
9%
Cell Adhesion Proteins
9%
Monoclonal Antibody
9%
Biochemistry, Genetics and Molecular Biology
Natalizumab
100%
C-Reactive Protein
27%
Integrin
18%
Body Weight
9%
Monoclonal Antibody
9%
Cell Adhesion Proteins
9%
Leukocyte
9%